English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Open

Presents the pdf analysis as premium feature

PDF Analysis

Insights

Presents the summarisation as premium feature

Summarisation

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

The consideration of a sentinel lymph node biopsy (SLNB) in patients with clinically node-negative high-risk primary cutaneous squamous cell carcinoma (cSCC) remains challenging. A paucity of evidence to guide clinicians results in varied management practices.1 Recently, the Brigham and Women's Hospital Tumor (BWH-T) staging for cSCC was proposed and seems to more precisely identify possible candidates for sentinel lymph node biopsy.2, 3, 4 We present a patient with a history of a double lung and renal transplantation with an aggressive cSCC who had a positive SNLB. We discuss considerations of a SLNB as it relates to solid organ transplant recipients (SOTRs) with cSCC.

Positive sentinel lymph node biopsy in a solid organ transplant recipient with a primary cutaneous squamous cell carcinoma of the nasal tip